Choroidal Neovascularization

• EMA withdrawal · 2025-04-14
  EMA Application withdrawn: Skojoy (aflibercept) — Amgen Technology (Ireland) UC

  EMA has withdrawn the marketing authorization application for Skojoy (aflibercept) submitted by Amgen Technology (Ireland) UC. The applicati…

• CLINICAL_TRIALS withdrawal · 2024-06-03
  Clinical Trial Update: Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks [Phase 3]

  A Phase 3 trial evaluating intravitreal bevacizumab for choroidal neovascularization associated with angioid streaks was terminated.

• CLINICAL_TRIALS withdrawal · 2017-01-06
  Clinical Trial Update: Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization in Angioid Streaks in Young Patients (ASTRID). [Phase 2]

  A Phase II study evaluating aflibercept for choroidal neovascularization associated with angioid streaks has been withdrawn. The sponsor lis…

• CLINICAL_TRIALS withdrawal · 2016-09-21
  Clinical Trial Update: Comparison Between Home Macular Perimeter and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With Choroidal Neovascularization (CNV)

  The clinical trial comparing a home macular perimeter with OCT for assessing visual field defects in choroidal neovascularization has been w…

• CLINICAL_TRIALS withdrawal · 2015-12-31
  Clinical Trial Update: Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration [Phase 1]

  Phase 1 trial evaluating imatinib mesylate with intravitreal ranibizumab for choroidal neovascularization due to age-related macular degener…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS withdrawal · 2015-08-13
  Clinical Trial Update: Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy [Phase 4]

  A Phase 4 clinical trial evaluating a triple treatment for detachment of the retinal pigment epithelium secondary to polypoidal choroidal va…

• CLINICAL_TRIALS withdrawal · 2015-07-07
  Clinical Trial Update: Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration [Phase 1]

  Phase 1 clinical trial evaluating the combination of efalizumab and intravitreal ranibizumab for age-related macular degeneration was withdr…

• CLINICAL_TRIALS withdrawal · 2014-11-21
  Clinical Trial Update: Does Vascular Endothelial Growth Factor (VEGF) or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With Choroidal NeoVascularization (CNV)? [NA]

  This clinical trial examining whether VEGF or CFH gene polymorphisms influence response to VEGF inhibitors in choroidal neovascularization a…

• CLINICAL_TRIALS withdrawal · 2014-01-14
  Clinical Trial Update: Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD [NA]

  A clinical trial comparing intravitreal bevacizumab versus combination therapy for choroidal neovascularization due to conditions other than…

• CLINICAL_TRIALS withdrawal · 2012-07-02
  Clinical Trial Update: Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks [Phase 1, Phase 2]

  The Phase 1/2 clinical trial of ranibizumab for choroidal neovascularization associated with angioid streaks has been withdrawn.